BUSINESS
Sumitomo Dainippon Files Thiotepa for Conditioning Regimen Prior to Autologous HSCT in Pediatric Solid Tumors
Sumitomo Dainippon Pharma said on July 4 that it has filed a new drug application (NDA) with the Japanese health ministry for thiotepa (development code: DSP-1958) as a conditioning treatment prior to autologous hematopoietic stem cell transplantation (HSCT) for pediatric…
To read the full story
BUSINESS
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
- Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
- Xospata Misses OS Endpoint in PIII Trial in Untreated FLT3-Mutated AML
March 10, 2026
- Enhertu Now under US Review for Post-Neoadjuvant HER2 Breast Cancer
March 10, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





